Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Stock Information for Precigen Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Precigen Inc.

Precigen to Participate in the 2024 Cantor Global Healthcare Conference
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
Precigen Announces Proposed $30 Million Public Offering of Common Stock
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.